Our proactive recommendations are simple and easy to use
These symptoms result from the progressive loss of dopamine-producing neurons in the brain
In research models, GLP-1 receptor activation is associated with glucose-dependent insulin secretion, suppression of glucagon release, slowed gastric emptying, and reduced food intake through central appetite-regulating circuits
[3] Other common adverse effects reported during the clinical trials include back pain, upper respiratory tract infections, melanocyte naevus, decreased appetite, migraine, dizziness, weakness, fatigue, lethargy, sleepiness, hot flashes, abdominal pain, diarrhea, vomiting, flushing, development of warts, spots, and freckles, and itchy skin (between 1% and 10% of people)
Whether semaglutide acts in a similar way is still unclear